1. Home
  2. HRMY vs LMAT Comparison

HRMY vs LMAT Comparison

Compare HRMY & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$35.34

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$96.14

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
LMAT
Founded
2017
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
HRMY
LMAT
Price
$35.34
$96.14
Analyst Decision
Buy
Buy
Analyst Count
9
5
Target Price
$44.11
$105.80
AVG Volume (30 Days)
910.7K
303.1K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
0.93%
EPS Growth
7.97
30.57
EPS
0.55
0.68
Revenue
$868,453,000.00
$249,602,000.00
Revenue This Year
$19.75
$14.21
Revenue Next Year
$12.88
$8.88
P/E Ratio
$65.09
$143.37
Revenue Growth
21.51
13.53
52 Week Low
$25.52
$79.01
52 Week High
$40.87
$118.01

Technical Indicators

Market Signals
Indicator
HRMY
LMAT
Relative Strength Index (RSI) 51.31 42.33
Support Level $35.05 $95.47
Resistance Level $35.47 $97.83
Average True Range (ATR) 1.59 3.46
MACD -0.20 -0.58
Stochastic Oscillator 46.08 2.30

Price Performance

Historical Comparison
HRMY
LMAT

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

Share on Social Networks: